|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2008
gptkb:FDA
|
|
gptkbp:atccode
|
N07 XX02
|
|
gptkbp:available_on
|
gptkb:tablet
|
|
gptkbp:brand
|
Xenazine
|
|
gptkbp:casnumber
|
58-41-7
|
|
gptkbp:chemical_formula
|
C19 H27 N3 O3
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
gptkb:depression
liver disease
MAO inhibitors
|
|
gptkbp:developed_by
|
Huntington's Disease Society of America
|
|
gptkbp:discontinued
|
in some countries
|
|
gptkbp:dosage_form
|
oral tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tetrabenazine
|
|
gptkbp:initial_dose
|
12.5 mg
|
|
gptkbp:interacts_with
|
gptkb:beer
antidepressants
antipsychotics
opioids
CYP3 A4 inducers
CYP2 D6 inhibitors
|
|
gptkbp:invention
|
gptkb:2020
|
|
gptkbp:lifespan
|
5 to 10 hours
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:maximum_dose
|
100 mg per day
|
|
gptkbp:mechanism_of_action
|
VMAT2 inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:previous_name
|
yes
|
|
gptkbp:produced_by
|
gptkb:Eisai_Inc.
|
|
gptkbp:related_to
|
gptkb:Brain
movement disorders
dopamine
|
|
gptkbp:research_focus
|
gptkb:neurodegenerative_diseases
Huntington's disease
Tourette syndrome
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
gptkb:depression
anxiety
fatigue
nausea
restlessness
drowsiness
insomnia
dry mouth
|
|
gptkbp:used_for
|
tardive dyskinesia
chorea associated with Huntington's disease
|
|
gptkbp:bfsParent
|
gptkb:Ingrezza
|
|
gptkbp:bfsLayer
|
6
|